Valuation: Corvus Pharmaceuticals, Inc.

Capitalization 1.27B 1.08B 991M 935M 1.74B 118B 1.77B 11.63B 4.55B 56.79B 4.76B 4.66B 202B P/E ratio 2026 *
-21.8x
P/E ratio 2027 * -19.5x
Enterprise value 1.27B 1.08B 991M 935M 1.74B 118B 1.77B 11.63B 4.55B 56.79B 4.76B 4.66B 202B EV / Sales 2026 *
-
EV / Sales 2027 * 151x
Free-Float
90.99%
Yield 2026 *
-
Yield 2027 * -
1 day-0.92%
1 week+1.55%
Current month+3.28%
1 month-1.37%
3 months+111.62%
6 months+96.49%
Current year+96.23%
1 week 14.38
Extreme 14.375
16.09
1 month 12.95
Extreme 12.95
16.09
Current year 6.39
Extreme 6.39
26.95
1 year 3.15
Extreme 3.15
26.95
3 years 0.98
Extreme 0.9777
26.95
5 years 0.61
Extreme 0.607
26.95
10 years 0.61
Extreme 0.607
26.95
Manager TitleAgeSince
Chief Executive Officer 74 2014-01-31
Director of Finance/CFO 71 2014-10-31
Chief Operating Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 66 2014-10-31
Chairman 74 2014-01-26
Director/Board Member 68 2015-11-30
Change 5d. change 1-year change 3-years change Capi.($)
-0.92%+1.55%+366.36%+1,352.88% 1.27B
-0.07%+5.53%-1.37%-9.49% 47.73B
+3.21%+2.48%+33.96%+21.19% 35.48B
+1.61%+3.22%+19.41%-11.11% 29.9B
+3.76%+57.66%+319.99%+588.98% 30.23B
+1.46%0.00%+31.46%+25.47% 28.75B
-3.25%+3.65%+57.04%+197.78% 14.93B
-1.00%+3.22%+3,409.12%+3,945.87% 14.74B
-0.28%-0.41%+70.01%+169.88% 14.81B
-0.84%+7.59%+36.25%+11.97% 14.42B
Average +0.37%+8.24%+434.22%+629.34% 23.23B
Weighted average by Cap. +1.01%+10.10%+281.69%+361.77%

Financials

2026 *2027 *
Net sales - 8.41M 7.12M 6.57M 6.19M 11.55M 784M 11.73M 77M 30.14M 376M 31.54M 30.88M 1.34B
Net income -65.05M -55.11M -50.81M -47.92M -89.37M -6.06B -90.81M -596M -233M -2.91B -244M -239M -10.34B -74.15M -62.82M -57.92M -54.62M -102M -6.91B -104M -679M -266M -3.32B -278M -272M -11.78B
Net Debt - -
Logo Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Employees
37
Date Price Change Volume
26-04-15 15.11 $ -0.92% 961,882
26-04-14 15.25 $ +0.53% 1,213,210
26-04-13 15.17 $ +0.46% 560,125
26-04-10 15.10 $ -3.64% 547,225
26-04-09 15.67 $ +5.31% 677,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.11USD
Average target price
35.17USD
Spread / Average Target
+132.74%

Quarterly revenue - Rate of surprise